Facilitating safe and effective drug development for more personalized and targeted patient populations.

What We Do

From the earliest days of Hanson Wade’s creation, we have sought to provide insights on the most cutting-edge and emerging facets of drug development. What began with a meet-up of academic scientists and biotech CEOs researching circulating tumor cells (CTCs) over 12 years ago, has become a conference portfolio of 200+ niche events, networks, and an industry-defining database service that supports over 25,000 biopharma customers each year.

Our Passion for Science Defines Us

Our passion for deeply researched science defines us, as does our desire to discover emerging fields of biopharma R&D that we can bring clarity to. As scientists by training, our product team talk to those at the forefront of the industry to ensure our products match the complexity and specificity of the drugs that are being developed. They discover the most critical challenges being faced and work with industry to define the solutions that are needed.

Across all therapeutic indications and drug modalities, we are resolute in our belief that for drug developers to get more targeted drugs to the right patients faster, we must provide information, products and services that are as precise and personalized as the drugs they are informing.

Our Relevance

As medicines become ever more precise in mechanism and personalized per patient, drug development itself has become increasingly complex. Specificity and granularity of information presented using relevant scientific language for customers to digest is therefore vital to ensure decisions are made accurately.

What We Deliver

Our customers only receive value that is 100% meaningful and relevant to them. Our products connect the right people and the right insights. Depth of information is what is required for drug development to succeed. We curate specific, timely and granular intelligence that applies to defined market niches.

Our Impact

Our product insights support critical and complex drug development decision-making. Where is the unmet need, who else is progressing, which candidates to prioritize and how to do it most effectively? Our information leads to stronger drug development decisions, improved patient outcomes and less time and cost wasted. Better drugs to patients, faster.

Microbiome AgBioTech Europe 2017 Highlights Video